Futura Medical plc, a pharmaceutical company developing sexual health products, has announced that its product Eroxon® has won the "New Product of the Year, Healthcare" category at the Boots Supplier Awards 2023. Eroxon® is a breakthrough treatment for erectile dysfunction (ED) and provides an alternative option for the 4.3 million men in the UK experiencing symptoms. The award is seen as recognition for the potential of Eroxon® to be a game changer in the treatment of ED. James Barder, CEO of Futura, expressed delight at the recognition and stated that Eroxon® is deserving of the award.
Eroxon® is a topical gel formulation that treats ED through a unique evaporative mode of action. It has been FDA approved in the US, CE marked in Europe, and UKCA marked in the UK. The product has a key claim of "Helps you get an erection within 10 minutes" and has been clinically proven to be effective. Futura has conducted two Phase 3 studies using Eroxon® in ED, which have demonstrated its rapid speed of onset and favorable benefit versus risk profile. The product is ideally suited for an "Over the Counter" classification.
Futura Medical is a pharmaceutical company that develops innovative products based on its proprietary transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and tailored for specific indications and applications. The company focuses on maximizing product differentiation and value creation while minimizing risk. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.